Fiche centre
Pusan National University Yangsan Hospital
Yangsan — South Korea
Essais liés9clinical trials
VilleYangsanlocalisation
PaysSouth Korealocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06211764
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| In-hospital staged complete revascularization | Maladie coronarienne | Non applicable | NCT07741721 | Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2) | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| TAR-200 | Cancer | Phase 3 | NCT06211764 | SunRISe-5 — A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | ACTIVE_NOT_RECRUITING |
| NS-089/NCNP-02 | Myopathies | Phase 2 | NCT05996003 | NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| NS-050/NCNP-03 | Myopathies | Phase 1/2 | NCT06053814 | NS-050/NCNP-03 in Boys With DMD (Meteor50) | ACTIVE_NOT_RECRUITING |
| Lenzumestrocel | Sclérose latérale amyotrophique | Phase 3 | NCT04745299 | ALSummit — Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS | COMPLETED |
| Adagrasib | Cancer | Phase 3 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING |
| PF-06939926 | Myopathies | Phase 3 | NCT04281485 | Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |